1
EXHIBIT 10.32
LIFEQUEST MEDICAL, INC.
SERIES B CUMULATIVE CONVERTIBLE PREFERRED STOCK
PURCHASE AGREEMENT
NOVEMBER 19, 1998
2
TABLE OF CONTENTS
ARTICLE I - PURCHASE AND SALE..................................................1
Section 1.1 Purchase and Sale; Purchase Price...................1
Section 1.2 Closing.............................................2
Section 1.3 Transactions at Closing.............................2
Section 1.4 Fees and Expenses...................................2
ARTICLE II - REPRESENTATIONS AND WARRANTIES OF THE COMPANY.....................2
Section 2.1 Organization, Standing and Qualification............2
Section 2.2 Capitalization......................................2
Section 2.3 Validity of Stock...................................3
Section 2.4 Subsidiaries........................................3
Section 2.5 Financial Statements................................3
Section 2.6 No Material Changes.................................4
Section 2.7 Permits.............................................5
Section 2.8 Insurance...........................................5
Section 2.9 Authorization; Approvals............................5
Section 2.10 No Conflict with Other Instruments..................6
Section 2.11 Labor Agreements and Actions........................6
Section 2.12 Title to Properties; Liens and Encumbrances.........6
Section 2.13 Compliance with Law and Other Instruments...........6
Section 2.14 Patents, Trademarks and Other Intangible Assets.....7
Section 2.15 Taxes...............................................7
Section 2.16 Contracts...........................................7
Section 2.17 Litigation..........................................8
Section 2.18 Securities Laws.....................................8
Section 2.19 Fees and Commissions................................8
Section 2.20 Interested Party Transactions.......................8
Section 2.21 ERISA...............................................9
Section 2.22 Environmental and Safety Laws.......................9
Section 2.23 SEC Reports.........................................9
Section 2.24 Full Disclosure.....................................9
ARTICLE III - REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE
PURCHASERS............................................................9
Section 3.1 Authorization; Approvals; No Conflicts..............9
Section 3.2 Investment Representations.........................10
Section 3.3 Investment Experience; Access to Information.......10
Section 3.4 Restrictions on Transfer...........................10
Section 3.5 Transfer Instructions..............................11
Section 3.6 Fees and Commissions...............................11
ARTICLE IV - CONDITIONS TO CLOSING OF THE PURCHASERS..........................11
i
3
ARTICLE V - CONDITIONS TO CLOSING OF THE COMPANY..............................12
ARTICLE VI - REGISTRATION RIGHTS..............................................12
Section 6.1 Shelf Registration.................................12
Section 6.2 Obligations of the Company.........................12
Section 6.3 Expenses of Registration...........................13
Section 6.4 Indemnification Regarding Registration Rights......13
Section 6.5 Reports Under the Exchange Act.....................16
Section 6.6 Assignment of Registration Rights..................16
ARTICLE VII - MISCELLANEOUS...................................................17
Section 7.1 Entire Agreement...................................17
Section 7.2 Survival of Representations and Warranties.........17
Section 7.3 Notices............................................17
Section 7.4 Amendments.........................................18
Section 7.5 Waiver and Consent.................................18
Section 7.6 Successors and Assigns.............................18
Section 7.7 Rights of Purchasers...............................18
Section 7.8 Execution and Counterparts.........................19
Section 7.9 No Third Party Beneficiaries.......................19
Section 7.10 Severability.......................................19
Section 7.11 Governing Law......................................19
ii
4
SCHEDULES
2.2 - Security Holders
2.5 - Financial Statements
2.6 - Material Changes
EXHIBITS
A - Form of Certificate of Designation and Preferences of
Series B Cumulative Convertible Preferred Stock
B - Form of Legal Opinion of the Company's Counsel
iii
5
SERIES B CUMULATIVE CONVERTIBLE PREFERRED STOCK
PURCHASE AGREEMENT
This AGREEMENT (the "Agreement"), dated as of November 19, 1998, is
entered into by and among LIFEQUEST MEDICAL, INC., a Delaware corporation (the
"Company"), RENAISSANCE CAPITAL GROWTH & INCOME FUND III, INC., a Texas
corporation, and RENAISSANCE US GROWTH & INCOME TRUST, PLC, a public limited
company registered in England and Wales (individually referred to as Renaissance
III and Renaissance PLC, respectively, and together with any permitted assignees
or successors in interest individually referred to as each or any "Purchaser"
and collectively referred to as the "Purchasers").
RECITAL
WHEREAS, the Purchasers desire to purchase 1,000 shares of Series B
Cumulative Convertible Preferred Stock, par value $.001 per share, of the
Company (the "Series B Preferred Stock"), having the rights, preferences,
privileges and restrictions set forth in the Company's Certificate of
Designation and Preferences of Series B Cumulative Convertible Preferred Stock
by resolution, substantially in the form attached hereto as EXHIBIT A (the
"Certificate of Designation"), and the Company desires to sell to the Purchasers
such shares of Series B Preferred Stock on the terms and subject to the
conditions set forth herein;
AGREEMENT
NOW, THEREFORE, in consideration of the premises, mutual covenants and
agreements hereinafter contained and for other good and valuable consideration,
the Company and the Purchasers hereby agree as follows:
ARTICLE I - PURCHASE AND SALE
Section 1.1 Purchase and Sale; Purchase Price. Subject to the
provisions of this Agreement, at Closing (as hereinafter defined), the Company
shall sell to the Purchasers, and the Purchasers shall purchase from the Company
1,000 shares of Series B Preferred Stock at the aggregate purchase price of
$1,000,000 (the "Purchase Price"), as follows:
PURCHASER PURCHASE PRICE NO. OF SHARES
--------- -------------- -------------
Renaissance Capital Growth & Income $500,000 500
Fund III, Inc.
Renaissance US Growth & Income Trust, PLC $500,000 500
1
6
Section 1.2 Closing. The purchase and sale of the Series B Preferred
Stock pursuant to Section 1.1 (the "Closing") shall take place at the offices of
Renaissance Capital Group, Inc., ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇,
▇▇▇▇▇▇, ▇▇▇▇▇ or at such other place as may be agreed upon by the Company and
the Purchasers, at 10:00 a.m., local time, on November 19, 1998 or at such other
time and date as may be agreed upon by the Company and the Purchasers (the
"Closing Date").
Section 1.3 Transactions at Closing. At the Closing, the Company shall
deliver to the Purchasers certificates for the shares of Series B Preferred
Stock to be issued and sold to the Purchasers hereunder duly registered in the
Purchasers' names, or in such other names as the Purchasers shall have specified
in writing to the Company, against payment in full by the Purchasers of the
Purchase Price by wire transfer of immediately available funds.
Section 1.4 Fees and Expenses. At Closing:
(a) The Company shall pay to Renaissance Capital Group, Inc.
a closing fee of $20,000.
(b) The Company shall pay the legal fees and expenses of the
Purchasers in connection with the preparation and negotiation of this Agreement
and the Closing.
ARTICLE II - REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company represents and warrants to the Purchasers that:
Section 2.1 Organization, Standing and Qualification. The Company is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware and has all requisite corporate power and authority to
own, lease and operate its property and assets and to conduct its business as
presently conducted and as proposed to be conducted by it. The Company has all
requisite corporate power and authority to enter into and perform its
obligations under this Agreement and to carry out the transactions contemplated
hereby. The Company is duly qualified to do business as a foreign corporation
and is in good standing in each jurisdiction in which the failure to so qualify
would have a material adverse effect on its assets, properties, condition
(financial or otherwise), operating results, prospects or business. Complete and
correct copies of the Certificate of Incorporation and Bylaws of the Company
have been delivered to the Purchasers.
Section 2.2 Capitalization. On the Closing Date, the authorized capital
stock of the Company shall consist of (a) 2,000,000 shares of preferred stock,
par value $.001 per share, of which 1,170 shares have been designated "Series A
Cumulative Convertible Preferred Stock," par value $.001 per share, of the
Company (the "Series A Preferred Stock"), and are issued and outstanding at the
Closing Date, 1,000 shares will be designated "Series B Cumulative Convertible
Preferred Stock" and no shares are issued or outstanding prior to the Closing
Date, and (b) 50,000,000 shares of common stock, par value $.001 per share (the
"Common Stock"), of which 7,212,742 shares are issued and outstanding, a total
of 3,595,818 shares are reserved for issuance pursuant to outstanding options,
warrants and debentures, 585,000 shares are reserved for issuance upon
conversion of the Series A Preferred Stock and 500,000 shares are reserved for
issuance upon conversion of the Series B Preferred Stock. The outstanding shares
of Common Stock are duly authorized and validly
2
7
issued, fully paid and nonassessable and not subject to preemptive rights.
Holders of shares of the Company's capital stock have no preemptive rights or
rights of first refusal. Except for the transactions contemplated by this
Agreement and as set forth in its SEC Filings (as defined in Section 2.23
herein) or on Schedule 2.2, there are (i) no outstanding warrants, options,
convertible securities or rights to subscribe for or purchase any capital stock
or other securities from the Company, (ii) no existing rights of security
holders to require the Company to register any securities of the Company or to
participate with the Company in any registration by the Company of its
securities, (iii) to the best knowledge of the Company, no agreements among
stockholders providing for the purchase or sale of the Company's capital stock
and (iv) no obligations (contingent or otherwise) of the Company to purchase,
redeem or otherwise acquire any shares of its capital stock or any interest
therein or to pay any dividend or make any other distribution in respect
thereof. The Company is not a party or subject to any agreement or
understanding, and, to the best knowledge of the Company, there is no agreement
or understanding between any persons, that affects or relates to the voting or
giving of written consents with respect to any security or the voting by a
director of the Company.
Section 2.3 Validity of Stock. The Series B Preferred Stock, when
issued, sold and delivered in accordance with the terms of this Agreement, will
be duly authorized and validly issued, fully paid and nonassessable, and will be
free of restrictions on transfer, other than restrictions on transfer under
applicable state and federal securities laws, and not subject to preemptive
rights. The Series B Preferred Stock shall have the terms, rights and
preferences set forth in the Certificate of Designation and Preferences of
Series B Cumulative Convertible Preferred Stock, which shall have been duly
executed and filed with the Secretary of State of the State of Delaware. The
Common Stock issuable upon conversion of the Series B Preferred Stock purchased
under this Agreement has been duly and validly reserved for issuance and, upon
issuance in accordance with the terms of the Certification of Designation, will
be duly and validly issued, fully paid, and nonassessable and will be free of
restrictions on transfer other than restrictions on transfer under applicable
state and federal securities laws.
Section 2.4 Subsidiaries. Except as set forth in its SEC Filings or on
Schedule 2.4, the Company (i) does not own or control, directly or indirectly,
any other corporation, partnership, association or business entity and (ii) is
not a participant in any joint venture, partnership, or similar arrangement.
Section 2.5 Financial Statements. The Company has furnished the
Purchasers with the Company's (i) unaudited balance sheet as of March 31, 1998
(the "Balance Sheet") and (ii) unaudited statements of income for the period
then ended (the "Statements of Income" and, together with the Balance Sheet, the
"Financial Statements"). The Financial Statements are attached hereto as
Schedule 2.5. The Financial Statements are true and correct in all material
respects, are in accordance with the books and records of the Company and have
been prepared in accordance with generally accepted accounting principles
("GAAP") consistently applied, and fairly and accurately present in all material
respects the financial position of the Company as of such date and the results
of its operations for the period then ended. Except as described in Schedule
2.5, the Company has no material liabilities, debts or obligations, whether
accrued, absolute or contingent, other than liabilities reflected or reserved
for in the Balance Sheet or disclosed in the notes to the Financial Statements.
Except as disclosed in the Financial Statements, the Company is not a guarantor
or indemnitor of any
3
8
indebtedness of any other person, firm or corporation. The Company maintains and
will continue to maintain a standard system of accounting established and
administered in accordance with GAAP.
Section 2.6 No Material Changes. Since March 31, 1998, except as set
forth in its SEC Filings or on Schedule 2.6, the Company has been operated in
the ordinary and usual course of business, and there has not been:
(a) any change in the (i) assets, liabilities, condition
(financial or otherwise) or business of the Company from that reflected in the
Balance Sheet, or (ii) operating results of the Company from that reflected in
the Statements of Income, in either case, except changes in the ordinary course
of business which have not been, in the aggregate, materially adverse;
(b) any damage, destruction or loss, whether or not covered by
insurance, materially and adversely affecting the assets, properties, condition
(financial or otherwise), operating results, prospects or business of the
Company (as such business is presently conducted and as it is proposed to be
conducted);
(c) any waiver or compromise by the Company of a valuable
right or of a material debt owed to it;
(d) any satisfaction or discharge of any lien, claim or
encumbrance or payment of any obligation by the Company, except in the ordinary
course of business and which is not individually or in the aggregate material to
the assets, properties, condition (financial or otherwise), operating results,
prospects or business of the Company (as such business is presently conducted
and as it is proposed to be conducted);
(e) any change or amendment to a material contract or
arrangement by which the Company or any of its assets or properties is bound or
subject, other than those that have not been, individually or in the aggregate,
materially adverse to the business of the Company;
(f) any material change in any compensation arrangement or
agreement with any employee, officer, director or stockholder of the Company;
(g) any sale, assignment or transfer of any patents,
trademarks, copyrights, trade secrets or other intangible assets;
(h) any resignation or termination of employment of any
"officer" of the Company, as such term is defined in Rule 3b-2 promulgated under
the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the
Company, to the best of its knowledge, does not know of the impending
resignation or termination of employment of any such officer;
(i) receipt of notice that there has been a loss of, or
material order cancellation by, any major customer of the Company;
4
9
(j) any mortgage, pledge, transfer of a security interest in,
or lien, created by the Company with respect to any of its material properties
or assets, except liens for taxes not yet due or payable;
(k) any loans or guarantees made by the Company to or for the
benefit of its employees, officers or directors or any members of their
immediate families, other than travel advances and other advances made in the
ordinary course of its business;
(1) any declaration, setting aside, or payment or other
distribution in respect of any of the Company's capital stock, or any direct or
indirect redemption, purchase or other acquisition of any of such stock by the
Company;
(m) to the best knowledge of the Company, any other event or
condition of any character which might materially adversely affect the assets,
properties, condition (financial or otherwise), operating results, prospects or
business of the Company (as such business is presently conducted and as it is
proposed to be conducted); or
(n) any agreement or commitment by the Company to do any of
the things described in this Section 2.6.
Section 2.7 Permits. The Company has all franchises, permits, licenses
and any similar authority necessary for the conduct of its business as now being
conducted by it, the lack of which could materially and adversely affect the
assets, properties, condition (financial or otherwise), operating results,
prospects or business of the Company. The Company is not in default in any
material respect under any of such franchises, permits, licenses or other
similar authority.
Section 2.8 Insurance. The Company has in full force and effect fire
and casualty insurance policies, with extended coverage, sufficient in amount
(subject to reasonable deductibles) to allow it to replace any of its material
properties that might be damaged or destroyed.
Section 2.9 Authorization; Approvals. All corporate action on the part
of the Company and its stockholders necessary for the authorization, execution,
delivery and performance of all its obligations under this Agreement and for the
authorization, issuance and delivery of the Series B Preferred Stock being sold
under this Agreement and of the Common Stock initially issuable upon conversion
of the Series B Preferred Stock has been (or will be) taken prior to the
Closing. This Agreement, when executed and delivered by or on behalf of the
Company, shall constitute the valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms. The Company has
obtained or will obtain prior to the Closing Date all necessary consents,
authorizations, approvals and orders, and has made all registrations,
qualifications, designations, declarations or filings with all federal, state or
other relevant governmental authorities required on the part of the Company in
connection with the consummation of the transactions contemplated by this
Agreement, except for such filings as may be required to be made after the
Closing in order to comply with the requirements of Regulation D promulgated
under the Securities Act of 1933, as amended (the "Securities Act") and
applicable state laws.
5
10
Section 2.10 No Conflict with Other Instruments. The execution,
delivery and performance of this Agreement will not result in any violation of,
be in conflict with, or constitute, with or without the passage of time or
giving of notice or both, a default under any terms or provisions of (i) the
Certificate of Incorporation or Bylaws of the Company; (ii) any judgment, decree
or order of any court or government agency or body having jurisdiction over the
Company or its properties; (iii) any agreement, contract, understanding,
indenture or other instrument to which the Company is a party or by which it is
bound, the effect of which would have a material adverse effect on the assets,
properties, condition (financial or otherwise), operating results, prospects or
business of the Company; or (iv) any statute, rule or governmental regulation
applicable to the Company.
Section 2.11 Labor Agreements and Actions. The Company is not bound by
or subject to (and none of its assets or properties is bound by or subject to)
any written or oral, express or implied, contract, commitment or arrangement
with any labor union, and no labor union has requested or, to the best knowledge
of the Company, has sought to represent any of the employees, representatives or
agents of the Company. There is no strike or other labor dispute involving the
Company pending, or, to the best knowledge of the Company, threatened, which
could have a material adverse effect on the assets, properties, condition
(financial or otherwise), operating results, prospects or business of the
Company (as such business is presently conducted and as it is proposed to be
conducted), nor is the Company aware of any labor organization activity
involving its employees. The Company is not aware that any "officer," as such
term is defined in Rule 3b-2 promulgated under the Exchange Act, intends to
terminate such person's employment with the Company, nor does the Company have a
present intention to terminate the employment of any of the foregoing persons.
Section 2.12 Title to Properties; Liens and Encumbrances. Set forth in
the SEC Filings is a description of the material real and personal property of
the Company owned, leased or licensed to or by the Company. Except as set forth
in the SEC Filings, (i) the Company has good and marketable title to all of the
properties and assets, both real and personal, tangible and intangible, that it
purports to own, including the properties and assets reflected on the Balance
Sheet (except as sold or disposed of after the date thereof in the ordinary
course of business and which in any event have not individually or in the
aggregate had a material adverse affect on the assets, properties, condition
(financial or otherwise), operating results, prospects or business of the
Company), and they are not subject to any mortgage, pledge, lien, security
interest, conditional sale agreement, encumbrance or charge except routine
statutory liens securing liabilities not yet due and payable and minor liens,
encumbrances, restrictions, exceptions, reservations, limitations and other
imperfections which do not materially detract from the value of the specific
asset affected or the present use of such asset; and (ii) the Company is not in
default or in breach of any provision of its leases or licenses other than
provisions which would not permit acceleration or termination of any such lease
or license and holds a valid leasehold or licensed interest in (y) the material
property it leases or (z) the property that is licensed to it.
Section 2.13 Compliance with Law and Other Instruments. The Company is
not in violation of any provision of (i) the Certificate of Incorporation or its
Bylaws, or (ii) any judgment, decree, order, statute, rule or governmental
regulation applicable to it, the violation of which would materially and
adversely affect the assets, properties, condition (financial or otherwise),
operating results, prospects or business of the Company. The Company is not in
violation or default in any material respect of any provision of any mortgage,
indenture, agreement, instrument or contract to
6
11
which it is a party or by which it is bound. To the best knowledge of the
Company, no employee of the Company is in violation of any term of any
employment contract, patent or other proprietary information, disclosure
agreement or any other contract or agreement relating to the employment of such
employee with the Company.
Section 2.14 Patents, Trademarks and Other Intangible Assets. All
material patents, patent applications, trademarks, service marks, trade names
and copyrights, and licenses and rights to the foregoing presently owned or held
by the Company are disclosed in the SEC Filings, none of which is in dispute or
in any conflict with the right of any other person or entity where an adverse
outcome would have a material adverse affect on the assets, properties,
condition (financial or otherwise), operating results, prospects or business of
the Company. Except as disclosed in the SEC Filings, the Company (i) owns or has
the unrestricted right to use, free and clear of all liens, claims and
restrictions, all patents, trademarks, service marks, trade names, copyrights
and trade secrets, including know-how, inventions, designs, processes, works of
authorship, computer programs (with the exception of normal software purchased
and sold as such) and technical data and information (collectively, the
"Intellectual Property"), and licenses and rights with respect to the foregoing,
used in the conduct of its business as now conducted or proposed to be conducted
without infringing upon or otherwise acting adversely to the right or claimed
right of any person, corporation or other entity, including former or current
consultants, or employees and former employers of its past and present employees
and (ii) is not obligated or under any liability whatsoever to make any payments
by way of royalties, fees or otherwise to any owner or licensee of, or other
claimant to, any patent, trademark, service ▇▇▇▇, trade name, copyright or other
intangible asset, with respect to the use thereof or in connection with the
conduct of its business or otherwise. There are no outstanding options, licenses
or agreements of any kind relating to the foregoing, nor is the Company bound by
or a party to any options, licenses or agreements of any kind with respect to
the patents, trademarks, service marks trade names, copyrights, trade secrets,
licenses, information and proprietary rights and processes of any other person
or entity. The Company has not received any communications alleging that the
Company has violated or, by conducting its business as proposed, would violate
any of the patents, trademarks, service marks, trade names, copyrights, trade
secrets or other proprietary rights or processes of any other person or entity.
Section 2.15 Taxes. The Company has accurately and timely filed all
federal income tax returns and all state and municipal tax returns that are
required to be filed by it and has paid or made provision for the payment of all
amounts due pursuant to such returns. The federal income tax returns of the
Company have not been audited by the Internal Revenue Service, and there are no
waivers in effect of the applicable statute of limitations for any period. No
deficiency assessment or proposed adjustment of federal income taxes or state or
municipal taxes of the Company is pending and the Company has no knowledge of
any proposed liability for any tax to be imposed.
Section 2.16 Contracts. Except as set forth in its SEC Filings or on
Schedule 2.16, the Company is not a party to any contract, and has no obligation
or commitment, in each case (i) involving aggregate payments by the Company or
having an aggregate value of more than $25,000, or (ii) that is otherwise
material to the business of the Company, or (iii) that is, or is reasonably
likely to be, materially adverse to the assets, properties, condition (financial
or otherwise), operating results, prospects or business of the Company. Except
as set forth in its SEC Filings or on Schedule 2.16, the Company has no
employment or consulting contracts, deferred compensation
7
12
agreements or bonus, incentive, profit-sharing or pension plans currently in
force and effect, or any understanding with respect to any of the foregoing, or
any non-competition and confidentiality agreements between the Company and any
employee of the Company, any consultant to the Company or any other entity.
Section 2.17 Litigation. Except as set forth in its SEC Filings or on
Schedule 2.17, there is no action, proceeding or governmental inquiry or
investigation pending or, to the best knowledge of the Company, threatened
against the Company or any of its officers, directors or employees (in their
capacity as such) or any of the Company's assets or properties before any court,
arbitration board or tribunal or administrative or other governmental agency.
The foregoing includes, without limiting its generality, actions pending or
known to the Company to be threatened involving (i) the prior employment of any
of the Company's employees or use by any of them in connection with the
Company's business of any information, property or techniques allegedly
proprietary to any of their former employers or (ii) any prior employees of the
Company in connection with rights to the Intellectual Property or any portion
thereof. The Company is not a party or subject to the provisions of any order,
writ, injunction, judgment or decree of any court or governmental agency or
instrumentality. There is no action, suit or proceeding by the Company currently
pending, or that the Company intends to initiate.
Section 2.18 Securities Laws. Assuming the accuracy of the
representations and warranties of the Purchasers set forth in Article III
hereof, the offer, sale and issuance of the shares of Series B Preferred Stock
to the Purchasers as provided herein are and will be exempt from the
registration and prospectus delivery requirements of the Securities Act and have
been registered or qualified (or are exempt from registration or qualification)
under all applicable state registration or qualification requirements.
Section 2.19 Fees and Commissions. The Company has not retained any
finder, broker, agent, financial advisor or other intermediary (collectively
"Intermediary") in connection with the transactions contemplated by this
Agreement, and the Company shall indemnity and hold harmless the Purchasers from
liability for any compensation to any Intermediary and the fees and expenses of
defending against such liability or alleged liability.
Section 2.20 Interested Party Transactions. Except as disclosed in its
SEC Filings, no executive officer or director of the Company or holder of more
than five percent (5%) of the capital stock of the Company or, to the best of
the Company's knowledge, any "affiliate" or "associate" (as these terms are
defined in Rule 405 promulgated under the Securities Act) of any such person or
entity or the Company has or has had, either directly or indirectly, (a) an
interest in any person or entity which (i) furnishes or sells services or
products which are furnished or sold or are proposed to be furnished or sold by
the Company, or (ii) purchases from or sells or furnishes to the Company any
goods or services, or (b) a beneficial interest in any material contract or
agreement to which the Company is a party or by which it may be bound or
affected. Except as disclosed in its SEC Filings, there are no existing material
arrangements or proposed material transactions between the Company and any
officer, director or holder of more than five percent (5%) of the capital stock
of the Company, or, to the best of the Company's knowledge, any affiliate or
associate of any such person.
8
13
Section 2.21 ERISA. The Company does not maintain, sponsor, or
contribute to any program or arrangement that is an "employee pension benefit
plan," an "employee welfare benefit plan," or a "multi-employer plan", as those
terms are defined in Sections 3(2), 3(l), and 3(37) of the Employee Retirement
Income Security Act of 1974, as amended.
Section 2.22 Environmental and Safety Laws. To the best knowledge of
the Company, the Company is not in violation of any applicable statute, law or
regulation relating to the environment or occupational health and safety, and no
material expenditures are or will be required in order to comply with any such
existing statute, law or regulation.
Section 2.23 SEC Reports. The Company has filed all reports,
registration or proxy statements, forms and documents with the SEC that it was
required to file since the date of the initial public offering of its Common
Stock (the "SEC Filings"), all of which have complied in all material respects
with all applicable requirements of the Securities Act and the Exchange Act. As
of their respective dates, each of the SEC Filings, including, without
limitation, any financial statements or schedules included therein, did not
contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances under which they were made, not misleading. None of
the Company's subsidiaries is required to file any reports, statements, forms or
other documents with the SEC.
Section 2.24 Full Disclosure. Neither the representations and
warranties or the schedules to this Agreement contain or will contain, as of the
date thereon, any untrue statement of a material fact or omits or will omit to
state any material fact necessary to keep the statements contained herein or
therein from being misleading in any material respect.
ARTICLE III - REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE
PURCHASERS
The Purchasers represent and warrant to the Company that:
Section 3.1 Authorization; Approvals; No Conflicts. All corporate
action on the part of the Purchasers necessary for the authorization, execution,
delivery and performance of all their obligations under this Agreement has been
or will be taken prior to the Closing. This Agreement, when executed and
delivered by or on behalf of the Purchasers, shall constitute the valid and
binding obligation of the Purchasers, enforceable against the Purchasers in
accordance with its terms. The Purchasers have obtained or will obtain prior to
the Closing Date all necessary consents, authorizations, approvals and orders,
and have made all registrations, qualifications, designations, declarations or
filings with all federal, state or other relevant governmental authorities
required on the part of the Purchasers in connection with the consummation of
the transactions contemplated by this Agreement. The execution, delivery and
performance of this Agreement will not result in any violation of, be in
conflict with, or constitute, with or without the passage of time or giving of
notice or both, a default under any terms or provisions of (i) the respective
Certificates of Incorporation or Bylaws of the Purchasers; (ii) any judgment,
decree or order of any court or government agency or body having jurisdiction
over the Purchasers or their properties; (iii) any agreement, contract,
understanding, indenture or other instrument to which the Purchasers are a party
or by which they are bound, the effect of which would have a material adverse
effect on the assets, properties,
9
14
condition (financial or otherwise), operating results, prospects or business of
the Purchasers; or (iv) any statute, rule or governmental regulation applicable
to the Purchasers.
Section 3.2 Investment Representations. The Purchasers are acquiring
the Series B Preferred Stock (and any Common Stock into which the Series B
Preferred Stock may be converted) for the Purchasers' own accounts, for
investment purposes and not with a view to, or for sale in connection with, any
distribution of such shares.
Section 3.3 Investment Experience; Access to Information. The
Purchasers are "accredited investors," as that term is defined in Rule 501(a)
promulgated under the Securities Act. The Purchasers have been afforded prior to
the Closing Date the opportunity to ask questions of, and to receive answers
from, the Company and to obtain any additional information, written and oral, to
the extent the Company has such information or could have acquired it without
unreasonable effort or expense, all as necessary for the Purchasers to make an
informed investment decision with respect to the purchase of the Series B
Preferred Stock.
Section 3.4 Restrictions on Transfer. The Purchasers agree that (a)
they will not offer, sell, transfer, give, pledge, hypothecate or otherwise
dispose of the Series B Preferred Stock (or the Common Stock into which it may
be converted) or make any attempt to do the foregoing unless such offer, sale,
transfer, gift, pledge, hypothecation or other disposition is (i) registered
under the Securities Act and any applicable state securities law, or (ii) in
compliance with an opinion of counsel to the Purchasers, delivered to the
Company and reasonably acceptable to counsel for the Company, to the effect that
such offer, sale, pledge, hypothecation or other disposition thereof does not
violate the Securities Act or applicable state securities law, and (b) the
certificate(s) representing the Series B Preferred Stock (and any Common Stock
into which it may be converted) shall bear a legend stating in substance:
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
"ACT"), OR UNDER ANY APPLICABLE STATE SECURITIES LAWS AND ARE
"RESTRICTED SECURITIES" AS THAT TERM IS DEFINED IN RULE 144
UNDER THE ACT. NEITHER THE SHARES NOR ANY INTEREST THEREIN MAY
BE OFFERED FOR SALE, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE
DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE ACT AND SUCH STATE SECURITIES LAWS OR AN
EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS
WHICH, IN THE OPINION OF COUNSEL FOR THE HOLDER, WHICH COUNSEL
AND OPINION ARE REASONABLY SATISFACTORY TO THE COUNSEL FOR
THIS CORPORATION, IS AVAILABLE.
Upon request of a holder of Series B Preferred Stock (or the Common
Stock into which it has been converted), the Company shall remove the legend set
forth above from the certificates
10
15
evidencing such Series B Preferred Stock or Common Stock or issue to such holder
new certificates therefor free of such legend, if with such request the Company
shall have received an opinion of counsel selected by the holder and reasonably
satisfactory to the Company, in form and substance reasonably satisfactory to
the Company, to the effect that such Series B Preferred Stock or Common Stock is
not required by the Securities Act to continue to bear the legend.
Section 3.5 Transfer Instructions. The Purchasers agree that the
Company may provide for appropriate transfer instructions to implement the
provisions of Section 3.4 hereof.
Section 3.6 Fees and Commissions. The Purchasers have retained no
Intermediary in connection with the transactions contemplated by this Agreement,
and the Purchasers agree to indemnify and hold harmless the Company from
liability for any compensation to any Intermediary and the fees and expenses of
defending against such liability or alleged liability.
ARTICLE IV - CONDITIONS TO CLOSING OF THE PURCHASERS
The obligation of the Purchasers on the Closing Date to purchase the
Series B Preferred Stock shall be subject to each of the following conditions
precedent, any one or more of which may be waived by the Purchasers:
(a) Representations and Warranties. The representations and
warranties made by the Company herein shall be true and accurate in all material
respects on and as of the Closing Date as if made on the Closing Date.
(b) Performance. The Company shall have performed and complied
with all agreements and conditions contained herein and other documents incident
to the transactions contemplated by this Agreement required to be performed or
complied with by it prior to or at the Closing.
(c) Consents. The Company shall have secured all permits,
consents and authorizations that shall be necessary or required lawfully to
consummate the transactions contemplated by this Agreement, to issue the Series
B Preferred Stock to be purchased by the Purchasers and to issue the Common
Stock into which the Series B Preferred Stock may be converted.
(d) Compliance Certificates. The Company shall have delivered
to the Purchasers or their representative at the Closing an Officer's
Certificate to the effect that all conditions specified in subsections (a) to
(c), inclusive, have been fulfilled.
(e) Opinion of the Company's Counsel. The Purchasers shall
have received from counsel for the Company, a legal opinion, dated the Closing
Date and satisfactory in form and substance to the Purchasers, substantially in
the form attached hereto as EXHIBIT B.
(f) Certificate of Designation. The Certificate of Designation
shall have been duly filed with the Secretary of State of the State of Delaware.
11
16
(g) Proceedings and Documents. All corporate and other
proceedings in connection with the transactions contemplated by this Agreement
and all documents and instruments incident to such transactions shall be
reasonably satisfactory in substance and form to the Purchasers, and the
Purchasers shall have received all such counterpart originals or certified or
other copies of such documents as the Purchasers may reasonably request.
ARTICLE V - CONDITIONS TO CLOSING OF THE COMPANY
The obligation of the Company on the Closing Date to issue and sell the
Series B Preferred Stock to be purchased under this Agreement shall be subject
to the representations and warranties made by the Purchasers herein being true
and accurate on and as of such Closing Date.
ARTICLE VI - REGISTRATION RIGHTS
Section 6.1 Shelf Registration. The Company shall file a "shelf"
registration statement on an appropriate form under the 1933 Act (the "Shelf
Registration") covering all of the Common Stock into which the Series B
Preferred Stock is convertible (the "Registrable Securities") within ninety (90)
days from the Closing and shall use its best efforts to cause the Shelf
Registration to be declared effective and to keep the Shelf Registration
continuously effective until all of the Registrable Securities registered
therein cease to be Registrable Securities. The securities shall cease to be
Registrable Securities when (a) the Shelf Registration shall have become
effective under the Securities Act and such securities shall have been disposed
of pursuant to the Shelf Registration, or (b) such securities shall have been
sold as permitted by Rule 144 under the Securities Act. The Company agrees, if
necessary, to supplement or amend the Shelf Registration, as required by the
registration form utilized by the Company or by the instructions applicable to
such registration form or by the Securities Act, and the Company agrees to
furnish to the holders of the Registrable Securities copies of any such
supplement or amendment prior to its being used.
Section 6.2 Obligations of the Company. Whenever required to effect the
registration of any Registrable Securities pursuant to this Agreement, the
Company shall, as expeditiously as reasonably possible:
(a) Furnish to the Purchasers such numbers of copies of a
prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act, and such other documents as they may
reasonably request in order to facilitate the disposition of Registrable
Securities owned by them;
(b) Use all reasonable efforts to register and qualify the
securities covered by such registration statement under such other securities or
Blue Sky laws of such jurisdictions as shall be reasonably requested by the
Purchasers, provided that the Company shall not be required in connection
therewith or as a condition thereto to qualify as a broker-dealer in any states
or jurisdictions or to do business or to file a general consent to service of
process in any such states or jurisdictions;
(c) Notify each Purchaser of Registrable Securities covered by
such registration statement, at any time when a prospectus relating thereto and
covered by such registration statement
12
17
is required to be delivered under the Securities Act, of the happening of any
event as a result of which the prospectus included in such registration
statement, as then in effect, includes an untrue statement of a material fact or
omits to state a material fact required to be stated therein or necessary to
make the statements therein not misleading in the light of the circumstances
then existing; and
(d) In the event of the notification provided for in Section
6.2(c) above, the Company shall use its best efforts to prepare and file with
the SEC (and to provide copies thereof to the Purchasers) as soon as reasonably
possible an amended prospectus complying with the Securities Act.
(e) For so long as any Purchaser holds beneficially or of
record (including shares issuable upon the conversion of the Series B Preferred
Stock) five percent (5%) or more of the shares of Common Stock from time to time
outstanding, such Purchaser shall agree to any restrictions on its resale of the
Registrable Securities, whether in public or non-public transactions, for a
period not in excess of ninety (90) days in any period of twelve (12)
consecutive months, as required by the managing underwriter, representative or
selling agent of any public or private offering of securities by the Company and
shall execute and deliver to the Company and such managing underwriter,
representative or selling agent an agreement to such effect, if each other
director and executive officer of the Company and holder of five percent (5%) or
more of the shares of Common Stock from time to time outstanding likewise agrees
to such restrictions on resale and executes and delivers such an agreement.
Section 6.3 Expenses of Registration. All expenses (other than
underwriting discounts and commissions) incurred in connection with the
registration or sale of the Registrable Securities pursuant to this Section,
including, without limitation, all registration, filing and qualification fees,
printer's expenses, and accounting and legal fees and expenses of the Company,
shall be borne by the Company.
Section 6.4 Indemnification Regarding Registration Rights. If any
Registrable Securities are included in a registration statement under this
Section:
(a) To the extent permitted by law, the Company will indemnify
and hold harmless each Purchaser, the officers and directors of each Purchaser
and each person, if any, who controls such Purchaser or underwriter within the
meaning of the Securities Act or the Exchange Act, against any losses, claims,
damages, liabilities (joint or several) or any legal or other costs and expenses
reasonably incurred by them in connection with investigating or defending any
such loss, claim, damage, liability or action to which they may become subject
under the Securities Act, the Exchange Act or other federal or state law,
insofar as such losses, claims, damages, costs, expenses or liabilities (or
actions in respect thereof) arise out of or are based upon any of the following
statements, omissions or violations (each a "Violation"): (i) any untrue
statement or alleged untrue statement of a material fact with respect to the
Company or its securities contained in such registration statement, including
any preliminary prospectus or final prospectus contained therein or any
amendments or supplements therein; (ii) the omission or alleged omission to
state therein a material fact with respect to the Company or its securities
required to be stated therein or necessary to make the statements therein not
misleading; or (iii) any violation or alleged violation by the Company of the
Securities Act, the Exchange Act, any federal or state securities law or any
rule or regulation promulgated under the
13
18
Securities Act, the Exchange Act or any state securities law. Notwithstanding
the foregoing, the indemnity agreement contained in this Section 6.4(a) shall
not apply and the Company shall not be liable (i) in any such case for any such
loss, claim, damage, costs, expenses, liability or action to the extent that it
arises out of or is based upon a Violation which occurs in reliance upon and in
conformity with written information furnished expressly for use in connection
with such registration by any such Purchaser, underwriter or controlling person,
or (ii) for amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without the prior written
consent of the Company, which consent shall not be unreasonably withheld.
(b) To the extent permitted by law, each Purchaser who
participates in a registration pursuant to the terms and conditions of this
Agreement shall indemnify and hold harmless the Company, each of its directors
and officers who have signed the registration statement, each Person, if any,
who controls the Company within the meaning of the Securities Act or the
Exchange Act, each of the Company's employees, agents, counsel and
representatives, any underwriter and any other Purchaser selling securities in
such registration statement, or any of its directors or officers, or any person
who controls such Purchaser, against any losses, claims, damages, costs,
expenses, liabilities (joint or several) to which the Company or any such
director, officer, controlling person, employee, agent, representative,
underwriter, or other such Purchaser, or director, officer or controlling person
thereof, may become subject, under the Securities Act, the Exchange Act or other
federal or state law, only insofar as such losses, claims, damages, costs,
expenses or liabilities or actions in respect thereto arise out of or are based
upon any Violation, in each case to the extent and only to the extent that such
Violation occurs in reliance upon and in conformity with written information
furnished by such Purchaser expressly for use in connection with such. Each such
Purchaser will indemnify any legal or other expenses reasonably incurred by the
Company or any such director, officer, employee, agent representative,
controlling person, underwriter or other Purchaser, or officer, director or of
any controlling person thereof, in connection with investigating or defending
any such loss, claim, damage, liability or action; provided, however, that the
indemnity agreement contained in this Section 6.4(b) shall not apply to amounts
paid in settlement of any such loss, claim, damage, costs, expenses, liability
or action if such settlement is effected without the prior written consent of
the Purchaser, which consent shall not be unreasonably withheld.
(c) Promptly after receipt by an indemnified party under this
Section 6.4 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 6.4, deliver to
the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party shall
have the right to retain its own counsel, with the reasonable fees and expenses
of such counsel to be paid by the indemnifying party, if representation of such
indemnified party by the counsel retained by the indemnifying party would be
inappropriate due to actual or potential conflict of interests between such
indemnified party and any other party represented by such counsel in such
proceeding. The failure to deliver written notice to the indemnifying party
within a reasonable time of the commencement of any such action shall not
relieve the indemnifying party of its obligations under this Section 6.4, except
to the extent that the failure results in a failure of actual notice to the
indemnifying
14
19
party and such indemnifying party is materially prejudiced in its
ability to defend such action solely as a result of the failure to give such
notice.
(d) If the indemnification provided for in this Section 6.4 is
unavailable to an indemnified party under this Section 6.4 in respect of any
losses, claims, damages, costs, expenses, liabilities or actions referred to
herein, then each indemnifying party, in lieu of indemnifying such indemnified
party, shall contribute to the amount paid or payable by such indemnified party
as a result of such losses, claims, damages, costs, expenses, liabilities or
actions in such proportion as is appropriate to reflect the relative fault of
the Company, on the one hand and of the Purchaser, on the other, in connection
with the Violation that resulted in such losses, claims, damages, costs,
expenses, liabilities or actions. The relative fault of the Company, on the one
hand, and of the Purchaser, on the other, shall be determined by reference to,
among other things, whether the untrue or alleged untrue statement of the
material fact or the omission to state a material fact relates to information
supplied by the Company or by the Purchaser, and the parties' relative intent,
knowledge, access to information and opportunity to correct or prevent such
statement or omission.
(e) The Company, on the one hand, and the Purchasers, on the
other hand, agree that it would not be just and equitable if contribution
pursuant to this Section 6.4 were determined by a pro rata allocation or by any
other method of allocation which does not take account of the equitable
considerations referred to in the immediately preceding paragraph. The amount
paid or payable by an indemnified party as a result of losses, claims, damages,
costs, expenses, liabilities and actions referred to in the immediately
preceding paragraph shall be deemed to include, subject to the limitations set
forth above, any reasonable legal or other expenses incurred by such indemnified
party in connection with defending any such action or claim. Notwithstanding the
provisions of this Section 6.4, neither the Company nor the Purchasers shall be
required to contribute any amount in excess of the amount by which the total
price at which the securities were offered to the public exceeds the amount of
any damages which the Company or each such Purchaser has otherwise been required
to pay by reason of such Violation. No person guilty of fraudulent
misrepresentations (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who is not guilty of such
fraudulent misrepresentation.
Section 6.5 Reports Under the Exchange Act. So long as the Company has
a class of securities registered pursuant to Section 12 of the Exchange Act,
with a view to making available to the Purchasers the benefits of Rule 144 under
the Securities Act and any other rule or regulation of the SEC that may at any
time permit a Purchaser to sell securities of the Company to the public without
registration or pursuant to a shelf registration on Form S-3, if applicable, the
Company agrees to use its reasonable efforts to:
(a) Make and keep public information available, as those terms
are understood and defined in SEC Rule 144, at all times;
(b) File with the SEC in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act;
(c) Use its best efforts to include, upon notice of issuance,
all Common Stock covered by such registration statement on NASDAQ National
Market if the Common Stock is then
15
20
quoted on NASDAQ National Market; or list all Common Stock covered by such
registration statement on such securities exchange on which any of the Common
Stock is then listed; or, if the Common Stock is not then quoted on NASDAQ
National Market or listed on any national securities exchange, use its best
efforts to have such Common Stock covered by such registration statement quoted
on NASDAQ National Market or, at the option of the Company, listed on a national
securities exchange; and
(d) Furnish to any Purchaser, so long as the Purchaser owns
any Registrable Securities, (i) forthwith upon request a copy of the most recent
annual or quarterly report of the Company and such other SEC reports and
documents so filed by the Company, and (ii) such other information (but not any
opinion of counsel) as may be reasonably requested by any Purchaser seeking to
avail itself of any rule or regulation of the SEC which permits the selling of
any such securities without registration or pursuant to such form.
Section 6.6 Assignment of Registration Rights. Subject to the terms and
conditions of this Agreement, the right to cause the Company to register
Registrable Securities pursuant to this Agreement may be assigned by Purchaser
to any transferee or assignee of such securities; provided that said transferee
or assignee is a transferee or assignee of at least ten percent (10%) of the
Registrable Securities and provided that the Company is, within a reasonable
time after such transfer, furnished with written notice of the name and address
of such transferee or assignee and the securities with respect to which such
registration rights are being assigned; and provided, further, that such
assignment shall be effective only if immediately following such transfer the
further disposition of such securities by the transferee or assignee is
restricted under the Securities Act; it being the intention that so long as
Purchaser holds any Registrable Securities hereunder, either Purchaser or its
transferee or assignee of at least ten percent may exercise the registration
rights hereunder. Other than as set forth above, the parties hereto hereby agree
that the registration rights hereunder shall not be transferable or assigned and
any contemplated transfer or assignment in contravention of this Agreement shall
be deemed null and void and of no effect whatsoever.
ARTICLE VII - MISCELLANEOUS
Section 7.1 Entire Agreement. This Agreement constitutes the entire
agreement between the parties hereto and supersedes all prior agreements and
understandings, oral and written, between the parties hereto with respect to the
subject matter hereof. No party shall be liable or bound to any other party in
any manner by any warranties, representation, or covenants except as
specifically set forth herein or therein.
Section 7.2 Survival of Representations and Warranties. The warranties,
representations and covenants of the Company and the Purchasers contained in or
made pursuant to this Agreement shall survive the execution and delivery of this
Agreement and the Closing.
Section 7.3 Notices. All notices, requests, demands, consents and other
communications herein shall be in writing and shall be deemed, unless otherwise
specified herein, to have been duly given if personally delivered or mailed,
first-class certified mail, postage prepaid and return receipt requested or sent
by recognized overnight courier service or transmitted by telex or facsimile, as
follows:
16
21
(a) If to the Company:
LifeQuest Medical, Inc.
▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇
Attention: Chief Financial Officer
Facsimile number: (▇▇▇) ▇▇▇-▇▇▇▇
with a copy to (which shall not constitute
effective notice to the Company):
Fulbright & ▇▇▇▇▇▇▇▇ L.L.P.
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Esq.
Facsimile number: (▇▇▇) ▇▇▇-▇▇▇▇
(b) If to the Purchasers:
Renaissance Capital Growth & Income Fund III, Inc.
Renaissance US Growth & Income Trust, PLC
▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇-▇▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇
Attention: President
Facsimile number: (▇▇▇) ▇▇▇-▇▇▇▇
with a copy to (which shall not constitute
effective notice to the Purchasers):
▇▇▇▇▇, ▇▇▇▇▇▇ & ▇▇▇▇▇▇ LLP
3100 Bank One Center
▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇
Attn: ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Esq.
Facsimile number: (▇▇▇) ▇▇▇-▇▇▇▇
or such other addresses as each of the parties hereto may provide from time to
time in writing to the party. For purposes of computing the time periods set
forth in this Section 7.3, the delivery date shall be deemed to be (i) three (3)
days after the date of mailing, (ii) the date personally delivered or sent by
telex or facsimile, or (iii) the business day after the date sent by recognized
overnight courier service.
Section 7.4 Amendments. Any term of this Agreement may be amended only
with the written consent of the Company and the Purchasers. Any amendment
effected in accordance with this paragraph shall be binding upon each holder of
Series B Preferred Stock purchased under this
17
22
Agreement at the time outstanding (including Common Stock into which such Series
B Preferred Stock have been converted), each future holder of such securities,
and the Company.
Section 7.5 Waiver and Consent. No action taken pursuant to this
Agreement, including any investigation by or on behalf of any party, shall be
deemed to constitute a waiver by the party taking such action of compliance with
any party hereto or a breach of any representations, warranties, covenants or
agreements contained herein. The waiver by any party hereto of a breach of any
provision of this Agreement shall not operate or be construed as a waiver of any
preceding or succeeding breach, and no failure by any party to exercise any
right or privilege hereunder shall be deemed a waiver of such party's rights or
privileges hereunder or shall be deemed a waiver of such party's rights to
exercise the same at any subsequent time or times hereunder.
Section 7.6 Successors and Assigns. Except as otherwise expressly
provided in this Agreement, all of the terms of this Agreement shall be binding
upon and inure to the benefit of and be enforceable by the respective successors
and assigns of the parties hereto (including permitted transfers of any shares
of Series B Preferred Stock sold hereunder or any Common Stock issued upon
conversion thereof).
Section 7.7 Rights of Purchasers. The Purchasers shall have the
absolute right to exercise or refrain from exercising any right or rights that
the Purchasers may have by reason of this Agreement or any Series B Preferred
Stock, including the right to consent to the waiver of any obligation of the
Company under this Agreement and to enter into any agreement with the Company
for the purpose of modifying this Agreement or any agreement effecting any such
modification.
Section 7.8 Execution and Counterparts. This Agreement may be executed
in any number of counterparts, each of which shall be deemed an original, and
all of which together shall constitute one instrument.
Section 7.9 No Third Party Beneficiaries. Except as otherwise provided,
this Agreement has been and is made solely for the benefit of and shall be
binding upon the Company and the Purchasers and no other person shall acquire or
have any rights under or by virtue of this Agreement.
Section 7.10 Severability. Any provision of this Agreement that is
prohibited, unenforceable or not authorized in any jurisdiction shall, as to
such jurisdiction, be ineffective to the extent of such prohibition,
unenforceability or lack of authorization without invalidating the remaining
provisions hereof or affecting the validity, unenforceability or legality of
such provision in any other jurisdiction.
Section 7.11 GOVERNING LAW. THIS AGREEMENT AND THE LEGAL RELATIONS
AMONG THE PARTIES HERETO SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH
THE LAWS OF THE STATE OF TEXAS, WITHOUT REGARD TO ITS CONFLICTS OF LAW DOCTRINE.
18
23
IN WITNESS WHEREOF, the parties hereto have executed this Agreement by
their duly authorized officers as of the date first above written.
COMPANY:
LIFEQUEST MEDICAL, INC.
By:
------------------------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
Vice President and Chief Financial Officer
PURCHASERS:
RENAISSANCE CAPITAL GROWTH & INCOME
FUND III, INC.
By:
------------------------------------------
Name:
-----------------------------------------
Title:
-----------------------------------------
RENAISSANCE US GROWTH & INCOME
TRUST, PLC
By: Renaissance Capital Group, Inc.,
Investment Manager
By:
---------------------------------
Name:
--------------------------------
Title:
--------------------------------